These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1626488)

  • 1. Long-term strategies in the management of heart failure: looking beyond ventricular function and symptoms.
    Packer M
    Am J Cardiol; 1992 Jun; 69(18):150G-154G. PubMed ID: 1626488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.
    Packer M
    J Am Coll Cardiol; 1992 Jul; 20(1):248-54. PubMed ID: 1351488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
    Packer M
    Eur Heart J; 1988 Jun; 9 Suppl H():105-8. PubMed ID: 2901957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of treatment on survival in congestive heart failure.
    Pitt B; Cohn JN; Francis GS; Kostis JB; Packer M; Pfeffer MA; Swedberg K; Yusuf S
    Clin Cardiol; 1992 May; 15(5):323-9. PubMed ID: 1623652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical therapy and prognosis in chronic heart failure. Lessons from clinical trials.
    Ramahi TM; Lee FA
    Cardiol Clin; 1995 Feb; 13(1):5-26. PubMed ID: 7796432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure.
    Packer M
    Circulation; 1989 Dec; 80(6 Suppl):IV59-67. PubMed ID: 2688986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurohormonal response to ventricular failure: pharmacologic management.
    Pratt NG
    J Cardiovasc Nurs; 1993 Oct; 8(1):49-62. PubMed ID: 8106897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope.
    Packer M
    J Am Coll Cardiol; 1988 Nov; 12(5):1299-317. PubMed ID: 2844873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New knowledge on the subject of therapy in cardiac decompensation in the light of large trials].
    Camerini F; Perkan A; Sinagra G; Di Lenarda A; Pinamonti B; Zecchin M
    Ann Ital Med Int; 1994 Oct; 9 Suppl():68S-77S. PubMed ID: 7857761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the treatment of heart failure.
    Cohn JN
    Am J Cardiol; 1997 Dec; 80(11A):2L-6L. PubMed ID: 9412537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy of heart failure].
    Follath F
    Ther Umsch; 1993 Jun; 50(6):425-33. PubMed ID: 8351674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical aspects of differential drug therapy of chronic heart failure].
    Erdmann E; Beuckelmann D; Böhm M; Schwinger HG
    Z Kardiol; 1992; 81 Suppl 4():97-103. PubMed ID: 1290310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [First-line treatment of cardiac insufficiency: digitalis glycosides, diuretics, vasodilator agents or new cardiotonic agents?].
    Komajda M; Lechat P; Grosgogeat Y
    Presse Med; 1988 Apr; 17(15):747-50. PubMed ID: 2968553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic therapy of chronic heart failure.
    Hamad E; Mather PJ; Srinivasan S; Rubin S; Whellan DJ; Feldman AM
    Am J Cardiovasc Drugs; 2007; 7(4):235-48. PubMed ID: 17696565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sympathetic activity in patients with heart failure due to idiopathic dilated cardiomyopathy: effect of ACE inhibitors and other vasodilators].
    Langes K; Bleifeld W
    Herz; 1990 Jun; 15(3):164-70. PubMed ID: 2198217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of heart failure.
    Schrier RW; Abdallah JG; Weinberger HH; Abraham WT
    Kidney Int; 2000 Apr; 57(4):1418-25. PubMed ID: 10760077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurohormonal factors in heart failure. II].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 May; 49(5):317-27. PubMed ID: 8744385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congestive heart failure--pathophysiology and medical treatment.
    Remme WJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S36-52. PubMed ID: 2422492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotropic agents in the treatment of heart failure: despair or hope?
    Sasayama S
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):703-9. PubMed ID: 9110113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.